Publications by authors named "R Toyozawa"
Background: The efficacy and safety of sotorasib plus platinum-doublet chemotherapy in KRAS G12C-mutated non-squamous non-small cell lung cancer (non-Sq NSCLC) were previously reported with limited follow-up period.
Method: SCARLET was a single-arm phase II study of chemotherapy-naïve patients with KRAS G12C-mutated non-Sq NSCLC. Participants received sotorasib 960 mg daily plus four cycles of carboplatin (area under the curve, 5)/pemetrexed 500 mg/m, followed by sotorasib/pemetrexed until disease progression.
Introduction: HER2 mutations are reported to occur in 2%-5% of all cases of non-small cell lung cancer (NSCLC). The clinical outcomes in patients with HER2-mutant NSCLC treated with immune checkpoint inhibitors (ICIs) plus platinum-based chemotherapy as 1st line treatment still remain unclear.
Methods: Using the large-scale clinico-genomic database of LC-SCRUM-Asia, the clinico-genomic characteristics and therapeutic outcomes of patients with HER2-mutant NSCLC were investigated.
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced -positive nonsquamous NSCLC.
Methods: We previously reported the primary results of a randomized, open-label, phase 2 study comparing osimertinib plus bevacizumab with osimertinib monotherapy for this population.
Article Synopsis
- SCLC has traditionally been viewed as a single entity, hindering advances in treatment; however, identifying genetic differences is key to improving patient outcomes.
- A study analyzed over 1000 SCLC samples using genomic screening to identify five distinct genetic subgroups, which can respond differently to therapies, especially targeted treatments.
- The findings indicate that while certain subgroups, like the NSCLC and MYC subgroups, have poorer survival rates with standard treatments, others may benefit from specialized therapies, highlighting the importance of personalized medicine in SCLC management.
Article Synopsis
- Brigatinib is a next-generation TKI that targets ROS1 and was evaluated in a phase II study called the Barossa study for patients with ROS1-rearranged solid tumors, dividing participants into three cohorts based on their treatment history.
- The study included 51 patients, primarily with ROS1-rearranged NSCLC; cohort 1 saw a 71.4% response rate in TKI-naive patients, while cohort 2 had a 31.6% response rate for those previously treated with crizotinib.
- Overall, while brigatinib showed efficacy, especially in cohort 1, it did not produce any responses in patients with other solid tumors in cohort 3, and the safety profile was consistent with earlier